List of Excipients in Branded Drug SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN

Generic Drugs Containing SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN

Company	Ingredient	NDC	Excipient
Kenvue Brands LLC	naproxen sodium and pseudoephedrine hydrochloride	50580-434	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	naproxen sodium and pseudoephedrine hydrochloride	50580-434	HYPROMELLOSE
Kenvue Brands LLC	naproxen sodium and pseudoephedrine hydrochloride	50580-434	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE

SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN: Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN is an extended-release, fixed-dose oral product combining pseudoephedrine hydrochloride 120 mg with naproxen sodium 220 mg per caplet, based on U.S. product labeling for the 12-hour pressure-and-pain formulation. Its commercial value depends less on active-ingredient exclusivity than on reliable 12-hour release, tablet manufacturability, consumer tolerability, packaging, and brand positioning.[1]

The strongest excipient opportunities are controlled-release matrix design, tablet robustness, moisture protection, coating optimization, and differentiated versions that improve swallowing or reduce abuse potential. The product is likely exposed to generic and private-label competition because pseudoephedrine and naproxen are established OTC ingredients with limited compound-patent protection.

What is SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN?

The product is an OTC combination for nasal congestion, sinus pressure, headache, and minor aches associated with sinus conditions.

Attribute	Product profile
Brand	SUDAFED
Product	Sinus 12 Hour Pressure Plus Pain
Dosage form	Extended-release caplet
Pseudoephedrine dose	120 mg pseudoephedrine hydrochloride
Analgesic dose	220 mg naproxen sodium
Dosing interval	Every 12 hours, subject to label directions
Therapeutic categories	Nasal decongestant and analgesic
Primary release challenge	Sustained pseudoephedrine delivery without compromising naproxen dissolution
Commercial status	OTC branded combination product
Likely competitive set	Generic pseudoephedrine ER, naproxen products, combination sinus products, and private-label equivalents

Pseudoephedrine provides systemic nasal decongestant activity through vasoconstriction. Naproxen sodium provides analgesic and anti-inflammatory activity. The combination offers a two-symptom value proposition, but it also creates formulation and regulatory constraints because the decongestant and NSAID have different physicochemical and safety profiles.

What excipients are used in the 12-hour pressure-and-pain formulation?

Public labeling for the U.S. formulation identifies a conventional solid-dose excipient platform that may include microcrystalline cellulose, croscarmellose sodium, hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, talc, sodium lauryl sulfate, carnauba wax, titanium dioxide, and colorants.[1]

The exact function of each excipient is formulation-dependent, but the likely roles are:

Excipient class	Likely function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet strength and manufacturability
Hypromellose	Release-controlling polymer or film former	Central to 12-hour performance
Croscarmellose sodium	Disintegrant	Controls immediate breakup of non-matrix portions
Povidone	Binder	Improves granule and tablet integrity
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and content uniformity
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Talc	Anti-adherent or coating aid	Supports processing and coating
Sodium lauryl sulfate	Wetting or dissolution aid	Can improve wetting of hydrophobic components
Carnauba wax	Surface or release-modifying material	May support coating durability or modified release
Titanium dioxide and colorants	Opacification and product identification	Supports brand recognition and light protection

The formulation must balance two different release behaviors. Pseudoephedrine hydrochloride is highly water soluble and can release too rapidly from a conventional tablet. Naproxen sodium is also more soluble than naproxen acid, but its dissolution and gastrointestinal tolerability remain sensitive to particle size, wetting, compression, and coating conditions.

How does the excipient strategy support 12-hour release?

The most commercially important excipient function is sustained release of pseudoephedrine. A hydrophilic hypromellose matrix can hydrate after ingestion, form a gel layer, and control drug diffusion and matrix erosion. Polymer grade, viscosity, substitution type, concentration, and particle-size distribution can materially change the release profile.

A robust development strategy would evaluate:

1. Hypromellose viscosity grades and polymer loading.
2. Direct compression versus wet granulation.
3. Drug-to-polymer ratio.
4. Tablet porosity and compression force.
5. Coating permeability and weight gain.
6. Release behavior under different agitation conditions.
7. Alcohol sensitivity and dose-dumping risk.
8. Dissolution in fed and fasted media.
9. Stability after exposure to heat and humidity.

A formulation with too little polymer may release pseudoephedrine rapidly and fail the 12-hour profile. Excess polymer can produce incomplete release, oversized tablets, poor swallowing, or manufacturing problems. The target is a reproducible release curve that remains within approved specifications after storage.

What formulation patents could protect this product?

The active ingredients themselves are old and generally offer limited new-molecule patent value. Protection is more likely to arise from formulation, process, dosage-form, or packaging claims.

Potential patentable subject matter includes:

• A specific hypromellose matrix containing pseudoephedrine hydrochloride and naproxen sodium.
• Defined dissolution ranges at multiple time points.
• A bilayer tablet separating the decongestant and analgesic.
• A coated core that delivers pseudoephedrine over 12 hours.
• Particle-size limits for naproxen sodium.
• A manufacturing process that improves content uniformity or reduces degradation.
• Alcohol-resistant modified release.
• A low-moisture formulation with improved stability.
• A smaller caplet using high-density excipients.
• A tamper-resistant or abuse-deterrent pseudoephedrine dosage form.
• Packaging that limits moisture ingress or supports legal-sale controls.

A patent claim limited to a familiar excipient combination may face prior-art pressure. Stronger protection would usually require a demonstrated technical effect, such as a specific dissolution profile, improved stability, reduced dose dumping, or manufacturing advantage.

How strong is the patent estate for SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN?

The likely patent estate is moderate to weak at the active-ingredient level and potentially stronger at the formulation level.

Protection layer	Expected strength	Reason
Pseudoephedrine composition of matter	Low	Long-established OTC active
Naproxen composition of matter	Low	Long-established NSAID
Fixed-dose combination	Low to moderate	Combination may be old or vulnerable to obviousness challenges
12-hour release system	Moderate	Technical performance can support formulation claims
Specific excipient architecture	Moderate	Depends on unexpected results and claim breadth
Manufacturing process	Moderate	Stronger if it solves scale-up, uniformity, or stability problems
Packaging and abuse controls	Moderate	May generate incremental protection
Brand and trade dress	Commercially important	Trademark and consumer recognition can outlast patents

No Orange Book-listed patent should be assumed without product-specific FDA listing verification. Many OTC branded products are not protected through a traditional Orange Book patent strategy comparable to prescription drugs. Their defenses often rest on trademarks, distribution, shelf placement, consumer loyalty, regulatory compliance, and formulation know-how.

When does SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN lose exclusivity?

The product’s practical exclusivity is likely already limited because its active ingredients are established OTC substances. The key loss-of-exclusivity event is therefore not necessarily a single patent expiry date. It is the entry or expansion of compliant generic, store-brand, and private-label alternatives.

Relevant exclusivity categories include:

Exclusivity type	Relevance
New chemical entity exclusivity	Not expected for pseudoephedrine or naproxen
Prescription-style NCE patent barrier	Not the primary commercial protection
OTC monograph eligibility	Potentially important, depending on the exact combination and dosage form
NDA-based exclusivity	Relevant only if the product relies on an approved NDA pathway
Formulation patent term	Relevant if enforceable claims cover the release system
Trademark exclusivity	Long-lived and commercially significant
Retail channel exclusivity	Can delay direct substitution without preventing technical competition

Pseudoephedrine products also face federal sales restrictions under the Combat Methamphetamine Epidemic Act. Retail controls limit purchase quantities and require regulated sale procedures, but they do not create brand exclusivity.[2]

Are Paragraph IV challenges relevant to this product?

Paragraph IV litigation is relevant only if an abbreviated new drug application is filed against an NDA with listed patents. It is not automatically applicable to every OTC product or monograph-based generic.

For this product, the principal scenarios are:

1. A generic manufacturer relies on an OTC monograph pathway where permitted.
2. A manufacturer files an ANDA referencing an approved NDA.
3. A competitor challenges formulation patents through a Paragraph IV certification.
4. A private-label product enters through a contract manufacturer or authorized OTC pathway.
5. A competitor markets a therapeutically similar but non-identical product, such as pseudoephedrine with acetaminophen or ibuprofen.

The most relevant litigation risk would involve a listed controlled-release formulation patent rather than the basic use of pseudoephedrine or naproxen.

What FDA regulatory issues affect the product?

The product combines two regulated OTC active ingredients with different monograph histories. FDA compliance depends on the exact active-ingredient strengths, dosage form, labeling, combination rationale, and regulatory pathway.[3]

Key issues include:

• Whether the combination is covered by applicable OTC monograph conditions.
• Whether the 12-hour dosage form requires an approved application.
• Conformance with FDA labeling requirements for pseudoephedrine and naproxen.
• NSAID warnings concerning gastrointestinal bleeding, cardiovascular risk, and allergic reactions.
• Decongestant warnings concerning hypertension, cardiovascular disease, and drug interactions.
• Child-resistant or controlled-sale requirements applicable to pseudoephedrine.
• Dissolution and stability specifications for the extended-release dosage form.
• Manufacturing controls under current good manufacturing practice rules.
• Package labeling that prevents duplicate NSAID use or excessive pseudoephedrine intake.

An excipient substitution can trigger regulatory work if it changes dissolution, bioavailability, stability, impurity levels, or labeling-relevant performance. A generic developer cannot assume that a functionally similar polymer or lubricant is interchangeable without comparative quality data.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not supplying commodity excipients alone. It is selling a validated formulation platform that reduces development time and regulatory risk.

1. Extended-release polymer systems

Excipient suppliers can offer hypromellose grades optimized for high-solubility drugs such as pseudoephedrine. Value increases when the supplier provides:

• Release-modeling data.
• Scale-up guidance.
• Compendial documentation.
• Lot-to-lot viscosity control.
• Alcohol dose-dumping data.
• Stability performance.
• Direct-compression grades.

A polymer platform that delivers a reproducible 12-hour profile can become embedded in a generic formulation and create switching costs.

2. Co-processed excipients

Co-processed cellulose, silicified microcrystalline cellulose, and multifunctional filler-binder systems may improve flow, tablet strength, and compression speed. These products can help reduce caplet size or eliminate wet granulation.

The commercial pitch is strongest where the formulation has a high active load, poor flow, lubrication sensitivity, or a narrow dissolution window.

3. Taste and swallowability improvements

The caplet is intended for adults, but large or hard-to-swallow tablets can reduce adherence. Opportunities include:

• Smaller high-density tablets.
• Low-friction film coatings.
• Smooth, low-tack surfaces.
• Shape optimization.
• Bilayer or multilayer formats that reduce tablet volume.
• Fast-swallow coating systems compatible with modified release.

A smaller tablet can support line extensions and improve consumer acceptance without changing the active-ingredient dose.

4. Moisture and stability systems

Excipient and packaging suppliers can offer integrated moisture-control solutions using:

• Low-moisture excipients.
• Desiccant-integrated bottles.
• High-barrier blister films.
• Induction seals.
• Oxygen scavengers where justified.
• Moisture-resistant coatings.

The commercial value is greatest in humid markets and in supply chains with extended storage periods.

5. Abuse-resistant pseudoephedrine formats

Pseudoephedrine is subject to diversion controls. An excipient-enabled matrix or tamper-resistant tablet could reduce crushing, extraction, or rapid-release behavior. Such features would not eliminate legal sales requirements, but they could support retailer acceptance and product differentiation.

6. Sustainable excipient and packaging systems

Brands may seek lower-impact coating materials, reduced solvent use, recyclable blister structures, or lower-material packaging. Sustainability claims require substantiation, but packaging redesign can reduce cost as well as environmental burden.

How does the product compare with competing sinus medicines?

Product type	Decongestant	Analgesic	Typical differentiation
SUDAFED 12-hour pressure plus pain	Pseudoephedrine ER	Naproxen sodium	Long-duration congestion and pain relief
Pseudoephedrine-only ER	Pseudoephedrine ER	None	Lower formulation complexity
Pseudoephedrine plus acetaminophen	Pseudoephedrine	Acetaminophen	Familiar analgesic with different safety profile
Pseudoephedrine plus ibuprofen	Pseudoephedrine	Ibuprofen	Competing NSAID combination
Phenylephrine combinations	Phenylephrine	Often acetaminophen	Easier retail positioning but different efficacy perceptions
Nasal sprays	Topical decongestant	None or separate analgesic	Faster local effect and different abuse profile

The product’s main competitive advantage is convenience. Its main weakness is that naproxen introduces NSAID warnings and may be unsuitable for some consumers. A generic developer could compete on price, smaller tablet size, better swallowability, clearer labeling, or a more stable package rather than on active ingredients.

What generic launch risks exist?

Generic entry risk is high where the product can be reproduced through an established OTC or abbreviated pathway. The main barriers are technical rather than molecular:

• Matching the 12-hour dissolution profile.
• Demonstrating stability with alternative excipients.
• Controlling pseudoephedrine content uniformity.
• Avoiding naproxen-related degradation or coating interaction.
• Meeting tablet hardness and friability requirements.
• Managing supply of qualified modified-release polymers.
• Complying with pseudoephedrine distribution restrictions.
• Establishing an acceptable regulatory pathway for the combination.

A generic launch could occur through a national retailer, a pharmacy chain, or a contract-manufactured private label. Retail substitution would pressure branded pricing, especially if the generic matches the caplet appearance and dosing interval.

What licensing and partnership opportunities exist?

Potential licensing targets include:

• Modified-release polymer technology.
• Bilayer tablet architecture.
• Abuse-resistant pseudoephedrine delivery.
• High-barrier packaging.
• Co-processed excipient platforms.
• Manufacturing processes that reduce tablet weight or improve throughput.
• Regional rights for OTC combination products.
• Private-label supply agreements with retailers and pharmacy chains.

The most defensible licensing package would combine formulation know-how, comparative dissolution data, manufacturing parameters, and regulatory documentation. An excipient patent alone may have limited value unless it is tied to a specific drug product and measurable performance advantage.

Key Takeaways

• SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN relies on a fixed-dose combination of pseudoephedrine hydrochloride and naproxen sodium.
• The core formulation challenge is sustaining pseudoephedrine release for 12 hours while preserving naproxen dissolution and tablet manufacturability.
• Hypromellose, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and coating materials form the likely excipient platform.
• Active-ingredient patent protection is weak because both ingredients are established OTC substances.
• Formulation, manufacturing, packaging, and abuse-control patents offer the most plausible incremental protection.
• Generic and private-label competition is a material risk, particularly if the combination can use an OTC monograph or abbreviated regulatory route.
• The strongest commercial opportunities are validated extended-release polymer systems, smaller caplets, moisture-protective packaging, and pseudoephedrine abuse-resistant designs.
• Brand equity and retail execution may provide more durable protection than the active-ingredient patent estate.

FAQs

Is SUDAFED SINUS 12 HOUR PRESSURE PLUS PAIN an extended-release product?

Yes. The 12-hour presentation is designed to release pseudoephedrine over an extended period, typically using a polymer matrix, coating system, or related modified-release architecture.

Which excipient is most important for the 12-hour release profile?

Hypromellose is likely the principal release-controlling excipient, although polymer grade, concentration, tablet porosity, coating, and compression conditions collectively determine performance.

Can a generic manufacturer replace hypromellose with another polymer?

Potentially, but the replacement must preserve dissolution, stability, bioavailability, and manufacturing performance. A polymer substitution may require substantial comparative development and regulatory justification.

Does pseudoephedrine regulation prevent generic competition?

No. Pseudoephedrine sales controls restrict purchasing and distribution but do not prevent compliant generic or private-label products from competing.

Is naproxen safer than acetaminophen in combination sinus products?

Neither ingredient is universally safer. Naproxen carries NSAID-related gastrointestinal, cardiovascular, renal, and bleeding risks. Acetaminophen carries dose-dependent liver toxicity risk. Product selection depends on the consumer’s health status, concomitant medicines, and label instructions.

References

1. U.S. Food and Drug Administration. (n.d.). SUDAFED Sinus 12 Hour Pressure Plus Pain product labeling. DailyMed/National Library of Medicine.

2. U.S. Drug Enforcement Administration. (2006). Combat Methamphetamine Epidemic Act of 2005: Retail sales requirements for pseudoephedrine and ephedrine products. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (2023). Nasal decongestant drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. § 341.

4. U.S. Food and Drug Administration. (2023). Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. § 343.